AHL Partners LLP Takes $2.04 Million Position in Illumina, Inc. (ILMN)

AHL Partners LLP bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,760 shares of the life sciences company’s stock, valued at approximately $2,041,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. First Citizens Bank & Trust Co. grew its stake in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after purchasing an additional 12 shares in the last quarter. Patten Group Inc. grew its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares in the last quarter. Puzo Michael J grew its stake in Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after purchasing an additional 25 shares in the last quarter. Flagship Harbor Advisors LLC grew its stake in Illumina by 1.7% in the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after purchasing an additional 35 shares in the last quarter. Finally, Eqis Capital Management Inc. grew its stake in Illumina by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after purchasing an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 93.32% of the company’s stock.

Illumina, Inc. (ILMN) opened at 208.24 on Friday. The company has a market capitalization of $30.40 billion, a price-to-earnings ratio of 41.78 and a beta of 0.76. The company’s 50-day moving average price is $204.12 and its 200 day moving average price is $185.47. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.34.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662.00 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $0.86 earnings per share. On average, analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the completion of the sale, the director now directly owns 534,176 shares in the company, valued at $91,221,235.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total transaction of $29,827.95. The disclosure for this sale can be found here. Insiders have sold 196,516 shares of company stock valued at $38,713,871 over the last 90 days. Company insiders own 1.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.com-unik.info/2017/10/13/ahl-partners-llp-takes-2-04-million-position-in-illumina-inc-ilmn.html.

ILMN has been the topic of a number of recent research reports. Leerink Swann restated an “outperform” rating and issued a $225.00 target price (up previously from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price on the stock. in a research note on Wednesday, June 21st. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Morgan Stanley restated an “underweight” rating and issued a $122.00 target price (up previously from $115.00) on shares of Illumina in a research note on Monday, July 10th. Finally, Canaccord Genuity restated a “hold” rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $190.50.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit